Increased levels of circulating microparticles are associated with increased procoagulant activity in patients with cutaneous malignant melanoma

Laresche, C.; Pelletier, F.; Garnache‐Ottou, Francine; Lihoreau, Thomas; Biichlé, Sabéha; Mourey, Guillaume; Saas, Philippe; Humbert, Philippe; Seillès, Estelle; Aubin, F.

doi:10.1016/j.annder.2013.09.631

Cited by 13 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The analytical method chosen is also critical to obtain robust and stable quantification of MPs over a long time period . We adapted an FC method by using beads to allow reproducible delimitation of the MP quantification area. This method was validated in assessments of its repeatability, reproducibility, linearity, and detection limit.…”

Section: Discussionmentioning

confidence: 99%

How to quantify microparticles in RBCs? A validated flow cytometry method allows the detection of an increase in microparticles during storage

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

How to quantify microparticles in RBCs? A validated flow cytometry method allows the detection of an increase in microparticles during storage

et al. 2017

View full text Add to dashboard Cite

show abstract

“…A specific area that has received considerable attention is cancer-associated thrombosis. In general, increased MPs have been detected using numerous methodologies, including FCM, in patients with a variety of tumors (80)(81)(82)(83)(84)(85). Several studies have also shown a relative increase in MPs in cancer patients with thrombosis compared to cancer patients without thrombosis (86)(87)(88)(89).…”

Section: Microparticle Analysis In Thrombotic Disordersmentioning

confidence: 99%

Microparticle analysis in disorders of hemostasis and thrombosis

2015

View full text Add to dashboard Cite

Microparticles (MPs) are submicron vesicles released from the plasma membrane of eukaryotic cells in response to activation or apoptosis. MPs are known to be involved in numerous biologic processes, including inflammation, the immune response, cancer metastasis, and angiogenesis. Their earliest recognized and most widely accepted role, however, is the ability to promote and support the process of blood coagulation. Consequently, there is ongoing interest in studying MPs in disorders of hemostasis and thrombosis. Both phosphatidylserine (PS) exposure and the presence of tissue factor (TF) in the MP membrane may account for their procoagulant properties, and elevated numbers of MPs in plasma have been reported in numerous prothrombotic conditions. To date, however, there are few data on true causality linking MPs to the genesis of thrombosis. A variety of methodologies have been employed to characterize and quantify MPs, although detection is challenging due to their submicron size. Flow cytometry (FCM) remains the most frequently utilized strategy for MP detection; however, it is associated with significant technological limitations. Additionally, pre-analytical and analytical variables can influence the detection of MPs by FCM, rendering data interpretation difficult. Lack of methodologic standardization in MP analysis by FCM confounds the issue further, although efforts are currently underway to address this limitation. Moving forward, it will be important to address these technical challenges as a scientific community if we are to better understand the role that MPs play in disorders of hemostasis and thrombosis.

show abstract

“…Platelets, in addition to responding to agonists, generate microparticles in response to complement activation, shear forces, senescence, and cytoskeletal abnormalities [2]. Increased concentration or altered characteristics of plasma microparticles in vivo are associated with hypertension [7], cardiovascular disease [8], recurrent miscarriage [9], transfusion-related acute lung injury [10], bacterial endotoxin [11], hypercoagulability in type 2 diabetes [12], Crohn's disease [13], sepsis [14,15], and auto-immune diseases such as rheumatoid arthritis, psoriasis and asthma [16][17][18], and melanoma [19]. In addition, the proportional increase of microparticle content (MPC) relative to platelet concentration during storage of platelet concentrate (PC) can be attributed to different methods of separation or varying processing conditions [20].…”

Section: Introductionmentioning

confidence: 99%

Microparticle content of platelet concentrates is predicted by donor microparticles and is altered by production methods and stress

Maurer‐Spurej

Larsen

Labrie³

et al. 2016

Transfusion and Apheresis Science

View full text Add to dashboard Cite

In circulation, shedding of microparticles from a variety of viable cells can be triggered by pathological activation of inflammatory processes, by activation of coagulation or complement systems, or by physical stress. Elevated microparticle content (MPC) in donor blood might therefore indicate a clinical condition of the donor which, upon transfusion, might affect the recipient. In blood products, elevated MPC might also represent product stress. Surprisingly, the MPC in blood collected from normal blood donors is highly variable, which raises the question whether donor microparticles are present in-vivo and transfer into the final blood component, and how production methods and post-production processing might affect the MPC. We measured MPC using ThromboLUX in (a) platelet-rich plasma (PRP) of 54 apheresis donors and the corresponding apheresis products, (b) 651 apheresis and 646 pooled platelet concentrates (PCs) with plasma and 414 apheresis PCs in platelet additive solution (PAS), and (c) apheresis PCs before and after transportation, gamma irradiation, and pathogen inactivation (N = 8, 7, and 12 respectively). ThromboLUX-measured MPC in donor PRP and their corresponding apheresis PC samples were highly correlated (r = 0.82, P = .001). The average MPC in pooled PC was slightly lower than that in apheresis PC and substantially lower in apheresis PC stored with PAS rather than plasma. Mirasol Pathogen Reduction treatment significantly increased MPC with age. Thus, MPC measured in donor samples might be a useful predictor of product stability, especially if post-production processes are necessary.

show abstract

Increased levels of circulating microparticles are associated with increased procoagulant activity in patients with cutaneous malignant melanoma

Cited by 13 publications

References 0 publications

How to quantify microparticles in RBCs? A validated flow cytometry method allows the detection of an increase in microparticles during storage

How to quantify microparticles in RBCs? A validated flow cytometry method allows the detection of an increase in microparticles during storage

Microparticle analysis in disorders of hemostasis and thrombosis

Microparticle content of platelet concentrates is predicted by donor microparticles and is altered by production methods and stress

Contact Info

Product

Resources

About